FASCO Recipients for this quarter – Part 2
FASCO Recipients – Part 2
ASCO recently shared on X:
“Join us in congratulating our members who earned the Fellows of ASCO (FASCO) distinction this quarter! We’re grateful for their extraordinary volunteer service, dedication, and commitment to ASCO.
Learn more about FASCO distinction.”
Part 2 of the list of the doctors who received the FASCO distinction:
Ana Maria López is a Professor and Vice Chair of Medical Oncology at Sidney Kimmel Medical College and Chief of Cancer Services at Sidney Kimmel Cancer Center – Jefferson Health in New Jersey.
She is a board certified medical oncologist and her clinical expertise is in women’s malignancies, integrative medicine and oncology, and telehealth. Dr. Lopez was honored in February 2022 with a Lifetime Achievement Award from Al DÍA News Media.
Maryam Lustberg is the Director of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center, and Chief of Breast Medical Oncology at Yale Cancer Center. She is also an Associate Professor of Medicine (Medical Oncology).
She has been recognized for her patient-focused care with awards that include being rated by Forbes as one of the top breast medical oncologists in the nation and named to the Castle Connolly list of “Regional Top Doctors,” and “Exceptional Women in Medicine” for 2020.
Dr. Herbert H. F. Loong is an Associate Professor in the Department of Clinical Oncology at The Chinese University of Hong Kong (CUHK), with additional roles as Deputy Medical Director of the Phase 1 Clinical Trials Centre and founder of the Prince of Wales Hospital Adult Sarcoma Multidisciplinary Team.
Dr. Loong has co-founded key organizations like the Asia Pacific Oncology Drug Development Consortium (APODDC) and the Asia Pacific Coalition Against Lung Cancer (APCLC). His involvement in international oncology bodies, including ASCO and IASLC, underscores his commitment to advancing cancer research and treatment on a global scale.
Laurel J. Lyckholm is a Professor of Hematology/Oncology at West Virginia University School of Medicine since June 2021. She was previously a Clinical Professor at the University of Iowa (2015-2021) and a Professor and Program Director at Virginia Commonwealth University (1995-2014), where she developed palliative care and bioethics curricula and established a clinic for incarcerated patients.
Allison Magnuson is a geriatric oncologist specializing in the treatment of cancer in older adults and breast cancer. She is the SOCARE Clinic Director at Wilmot Cancer Institute and a Senior Instructor at the University of Rochester, with dual training in medical oncology and geriatrics. Her research focuses on improving outcomes for older cancer patients, particularly in cognition.
Dr. Monica Malik is a Radiation Oncologist at a leading University Academic Hospital in India. Her research focuses on Neuro-oncology, Breast cancer, and Palliative care. She is an advocate for incorporating palliative and supportive care into routine oncological care. She serves as a member of the Cancer Technical Committee Telangana State (2021–present), the ASCO Resource Stratified Guidelines Advisory Board (2017–present), and the ASCO International Affairs Committee (2014–2016).
Dr. Santos Eric Martin is a hematologist/oncologist at Christiana Care’s Helen F. Graham Cancer Center, specializing in leukemia, stem cell and bone marrow transplantation, and molecular diagnostics. He holds roles as the clinical investigator for the Cancer and Acute Leukemia Group B/ECOG and leads the Provenge Cellular Prostate Cancer Immunotherapy Trial. Dr. Martin is also a clinical associate professor at Thomas Jefferson University.
Jane Lowe Meisel, MD is an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, with a secondary appointment in the Department of Gynecology and Obstetrics. She has been a practicing physician at the Glenn Family Breast Center at Winship Cancer Institute since 2015. Dr. Meisel specializes in women’s health and cancers affecting women, including breast, cervical, endometrial, and ovarian cancers.
Funda Meric-Bernstam is the Chair of the Department of Investigational Cancer Therapeutics and the Phase I Program at MD Anderson Cancer Center. She also serves as the Medical Director of the Institute for Personalized Cancer Therapy (IPCT) and holds The Nellie B. Connally Chair in Breast Cancer at MD Anderson.
Her clinical research focuses on Phase I/II trials, including novel mechanisms of action, combination therapies, and biomarkers for predicting and monitoring drug response. She is a Professor at The University of Texas MD Anderson Cancer Center.
Dr. Joseph Mikhael is a Professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope Cancer Center. He also serves as the Chief Medical Officer of the International Myeloma Foundation (IMF).
Dr. Mikhael is a consultant hematologist and Director of Myeloma Research at the HonorHealth Research Institute, where he conducts Phase 1 clinical trials. He recently completed a term as Councilor on the American Society of Hematology Executive and led the ASCO guidelines for multiple myeloma. His clinical expertise includes plasma cell disorders such as multiple myeloma, amyloidosis, and Waldenström’s macroglobulinemia.
Kathleen N. Moore is the Associate Director of Clinical Research at the Stephenson Cancer Center and the Director of the Oklahoma TSET Phase I Program. She is also a Professor in the Section of Gynecologic Oncology. Dr. Moore’s clinical research focuses on drug development and Phase I trials.
Michael J. Morris, MD is the prostate cancer section head in the Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center in New York. He specializes in treating patients with prostate cancer, particularly those with metastatic disease or at high risk for metastasis.
His research focuses on bone and tumor-directed radiopharmaceuticals and developing novel imaging biomarkers. Dr. Morris is the medical director of the Prostate Cancer Clinical Trials Consortium and chairs the Genitourinary Committee of the National Cancer Institute’s Alliance for Clinical Trials in Oncology.
Dr. Eileen M. O’Reilly is the Winthrop Rockefeller Endowed Chair in Medical Oncology at Memorial Sloan Kettering Cancer Center. She leads the Hepatopancreaticobiliary/Neuroendocrine Cancers section and is Co-Director of Medical Initiatives at the David M. Rubenstein Center for Pancreatic Cancer. She is also an Attending Physician at MSK, a Professor at Weill Cornell Medical College, and Chair of the Human Research Protection Program/IRB. Her work focuses on pancreatic and hepatobiliary malignancies.
Dr. Aparna R. Parikh is an Associate Professor of Medicine at Harvard Medical School and a Gastrointestinal Oncologist at Massachusetts General Hospital, where she has been practicing since September 2016. She is affiliated with the Tucker Gosnell Center for Gastrointestinal Cancers and the Henri and Belinda Termeer Center for Targeted Therapies. Dr. Parikh’s clinical interests include clinical trials, clinical research, gastrointestinal cancer, global health, immunotherapy, and Phase I clinical trials.
Mark D. Pegram, MD is the Suzy Yuan-Huey Hung Endowed Professor of Medical Oncology at Stanford University School of Medicine and the Associate Director of Clinical Research at the Stanford Comprehensive Cancer Institute (SCCI). He also serves as the Associate Dean for Clinical Research Quality at Stanford University and is the Medical Director of the Stanford Clinical Translational Research Unit, which focuses on first-in-human Phase I clinical trials. Dr. Pegram’s research in breast cancer centers on the HER2 gene and the development of novel treatments for HER2-positive metastatic breast cancer.
Dr. Brian E. Persing is an oncologist affiliated with the Singing River Health System in Pascagoula, Alabama. He has expertise in treating lung cancer, breast cancer, prostate cancer, and other conditions. Dr. Persing is also an Assistant Professor at the University of South Alabama Health.
Dr. Reckamp is a Professor of Medicine and the Director of the Division of Medical Oncology at Cedars-Sinai Medical Center. Her research focuses on developing novel therapies and biomarkers for lung cancer, particularly targeted therapies.
Dr. Reckamp is an active member of the Southwest Oncology Group (SWOG) and its Lung Cancer Committee. She also represented City of Hope on the National Comprehensive Cancer Network Guidelines Committee, shaping treatment guidelines for thoracic malignancies from 2008 to 2020.
Dr. Lorna Rodriguez-Rodriguez is the Vice Chair of Surgery and a Professor in the Division of Gynecologic Oncology at City of Hope National Medical Center, focusing on ovarian cancer research, CD44 receptor targeting, and novel immunotherapies. She also serves on the Enterprise Leadership Team.
From 2000 to 2019, she was the Chief of Gynecologic Oncology at Rutgers Cancer Institute of New Jersey and a Professor at Rutgers Robert Wood Johnson Medical School, where she led extensive ovarian cancer research and mentored many post-graduate students.
Dr. Trevor J. Royce is a radiation oncologist based in Chapel Hill, North Carolina, affiliated with Providence Veterans Affairs Medical Center and UNC Hospitals. He specializes in advanced radiation techniques and personalized treatment plans for cancer patients. Dr. Royce is involved in both clinical practice and research, focusing on optimizing radiation treatments, improving patient outcomes, and integrating novel therapies.
Kathryn Ruddy, MD, MPH is an Associate Professor of Oncology and the Director of Cancer Survivorship at the Mayo Clinic. She serves on the NCCN Survivorship Guidelines Committee and is the Vice Chair of the Symptom Intervention Committee of the Alliance for Clinical Trials in Oncology. Dr. Ruddy is board certified in hematology, medical oncology, and internal medicine.
Dr. Anne Frances Schott is a Professor of Medicine and the Associate Director of Clinical Research at the Rogel Cancer Center, University of Michigan. She has been in this role since September 2016. Dr. Schott is a specialist in breast cancer, focusing her research on developing and testing new treatments through clinical trials. She has also been a Clinical Professor of Medicine at the University of Michigan since July 1996.
Ramy Sedhom holds positions as Assistant Professor of Hematology and Oncology at Perelman School of Medicine and Director of Medical Oncology and Palliative Care at Penn Medicine’s Princeton Medical Center. His work focuses on palliative care integration, geriatric assessment, psycho-oncology, caregiver distress, and remote patient monitoring, with publications in leading journals.
Nationally, he contributes to guideline panels and committees, including the NCCN Guideline Panel for Older Adults with Cancer, and leadership roles within ASCO.
Dr. James A. Talcott is an oncologist based in Yakima, Washington. He received his medical degree from Yale School of Medicine and has over 20 years of experience in the field. Dr. Talcott is the Senior Medical Director, Oncology for Eviti at NantHealth. He is a medical oncologist and outcomes researcher and has previously served as the Oncology Care Model Medical Director.
Dr. Ulka Vaishampayan is a Professor of Oncology at the University of Michigan, Ann Arbor. She leads the Translational and Clinical Research Program and directs the Phase 1 Program at the University of Michigan Rogel Cancer Center.
Dr. Vaishampayan is the Chair of the SWOG Advanced Renal Committee, a member of the NCI Renal Task Force, and serves on the board of the Michigan Society of Hematology/Oncology. She specializes in treating genitourinary malignancies, including prostate, bladder, and renal cell cancers, with a research focus on translational drug and biomarker development.
Ana Velázquez Mañana is an Assistant Professor of Medicine in the UCSF Division of Hematology/Oncology at Zuckerberg San Francisco General and a thoracic oncologist at the UCSF Helen Diller Family Comprehensive Cancer Center.
She serves as Assistant Director of Diversity, Equity, Inclusion, and Accessibility for Trainees of the UCSF Helen Diller Family Comprehensive Cancer Center and co-chairs the UCSF Department of Medicine Fellowship Diversity Committee. Her research, advocacy, and education efforts are focused on promoting and advancing health equity and workforce diversity.
Dr. Vamsi Velcheti serves as a Scientific Mentor at NYU Endless Frontier Lab and is the Co-Director of the Cancer Biology Program at NYU Grossman School of Medicine, where he has also been directing the Thoracic Oncology Program since September 2018. Additionally, he is a Professor of Medicine at New York University. His clinical focus is on thoracic malignancies, specifically lung cancer and mesothelioma.
Dr. Jack West is the Vice President of Clinical Development at Summit Therapeutics, based in San Mateo, California. He founded and led GRACE from 2007 to 2024. He also served as President of Go West Health Care Consulting since 2006, Vice President of Network Strategy and Clinical Executive Director at AccessHope and Medical Oncologist and Clinical Associate Professor at City of Hope. Jack specializes in thoracic oncology, genitourinary oncology, clinical trials development and CME development.
Dr. Grant R. Williams is a Medical Oncologist and Geriatrician at the University of Alabama at Birmingham, focusing on the management of gastrointestinal malignancies. His research and clinical care emphasize the intersection of cancer and aging, aiming to provide personalized, evidence-based care for frail and vulnerable older adults with cancer.
Dr. Williams is an Associate Professor in Hematology & Oncology and holds several roles as an Associate Scientist across various research centers at the University of Alabama at Birmingham.
Stephanie F. Williams is an oncologist at Grand Rapids, Michigan. She is affiliated with multiple hospitals in the area, including Corewell Health Grand Rapids Hospitals-Blodgett and Butterworth and Bronson Methodist Hospital. She received her medical degree from University of Chicago Division of the Biological Sciences The Pritzker School of Medicine.
For more information about FASCO awardees, click here.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023